Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Azacitidine + JNJ-75276617 + Venetoclax|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Azacitidine||Vidaza||azacytidine|CC-486|5-azacytidine|5-AC|U-18496|Onureg||DNMT inhibitor (Pan) 5||Vidaza (azacitidine) is a cytidine analog that incorporates into DNA and RNA and binds to DNA methyltransferases (DNMTs), resulting in DNMT degradation and decreased DNA methylation, and leading to increased tumor cell death (PMID: 28159832, PMID: 28067760). Vidaza (azacitidine) is FDA-approved for use in patients with some subtypes of myelodysplastic syndrome and Onureg (azacitidine) is FDA approved for use in continued treatment of acute myeloid leukemia(FDA.gov).|
|JNJ-75276617||JNJ 75276617|JNJ75276617||MEN1-KMT2A Inhibitor 6||JNJ-75276617 inhibits the interaction between menin and MLL, leading to decreased expression of target genes, potentially resulting in inhibition of cell proliferation of tumor cells harboring gene rearrangements, duplications or amplifications in KMT2A or gene alterations in NPM1 (NCI Drug Dictionary).|
|Venetoclax||Venclexta||ABT-199|RG7601|GDC-0199|ABT119|Venclyxto||BCL2 inhibitor 25||Venclexta (venetoclax) is a BH3-mimetic that binds to and inhibits BCL2, resulting in increased tumor cell apoptosis (PMID: 26589495, PMID: 25048785). Venclexta (venetoclax) is FDA approved for use in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), and in combination with chemotherapy in patients 75 years old or older with newly-diagnosed acute myeloid leukemia (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT05453903||Phase I||JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617 + Venetoclax Azacitidine + JNJ-75276617||A Study of JNJ-75276617 in Combination With Acute Myeloid Leukemia (AML) Directed Therapies||Recruiting||USA | ITA | FRA | ESP | DEU||2|